Murphy Andrew J sold 255 shares of REGENERON PHARMACEUTICALS, INC. at $963.60 for −$246k on Nov 17, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Co-Chief Scientific Officer
Co-Chief Scientific Officer
Filed Nov 18, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$245,718Shares × reported price
Shares traded
255Common Stock
Price per share
$963.60Reported price. Read footnotes for ranges.
% of reported position traded
0.54%This security and ownership context
Holdings after
47,119Direct
Trade date
Nov 17, 2026Sell
Filed
Nov 18, 2026, 4:07 PM ET1-day reporting delay
Accession
0001796226-26-000006Code S · Transaction 405688
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 47,374 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 16, 2026Option exercise17,000$381.92$6,492,640Trade 405672
Nov 17, 2026Sell93$949.69−$88,321.17Trade 405674
Nov 17, 2026Sell74$950.61−$70,345.14Trade 405675
Nov 17, 2026Sell298$951.75−$283,621.50Trade 405676
Nov 17, 2026Sell220$952.75−$209,605Trade 405677
Nov 17, 2026Sell671$953.69−$639,925.99Trade 405678
Nov 17, 2026Sell313$954.45−$298,742.85Trade 405679
Nov 17, 2026Sell313$955.48−$299,065.24Trade 405680
Nov 17, 2026Sell346$956.70−$331,018.20Trade 405681
Nov 17, 2026Sell202$957.53−$193,421.06Trade 405682
Nov 17, 2026Sell244$958.27−$233,817.88Trade 405683
Nov 17, 2026Sell506$959.45−$485,481.70Trade 405684
Nov 17, 2026Sell257$960.65−$246,887.05Trade 405685
Nov 17, 2026Sell584$961.45−$561,486.80Trade 405686
Nov 17, 2026Sell295$962.70−$283,996.50Trade 405687
Nov 17, 2026Sell340$964.36−$327,882.40Trade 405689
Nov 16, 2026Tax withholding11,989$960.02−$11,509,679.78Trade 405673
Nov 16, 2026Option exercise17,000$0.00$0Trade 405690
19 transaction rows in this filing. Joint filers share the same rows.

REGN price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
REGN · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 25, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −16%1w ago −3.1%1d ago +0.7%
Returns since7d30d90d180d1y

Footnotes in full

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 7, 2026. F2: Represents volume-weighted average price of sales of 74 shares of Company stock on November 17, 2026 at prices ranging from $950.50 to $950.61. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F3: Represents volume-weighted average price of sales of 298 shares of Company stock on November 17, 2026 at prices ranging from $951.41 to $951.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F4: Represents volume-weighted average price of sales of 220 shares of Company stock on November 17, 2026 at prices ranging from $952.54 to $952.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F5: Represents volume-weighted average price of sales of 671 shares of Company stock on November 17, 2026 at prices ranging from $953.18 to $953.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F6: Represents volume-weighted average price of sales of 313 shares of Company stock on November 17, 2026 at prices ranging from $954.26 to $954.60. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F7: Represents volume-weighted average price of sales of 313 shares of Company stock on November 17, 2026 at prices ranging from $955.02 to $955.68. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F8: Represents volume-weighted average price of sales of 346 shares of Company stock on November 17, 2026 at prices ranging from $956.17 to $956.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price F9: Represents volume-weighted average price of sales of 202 shares of Company stock on November 17, 2026 at prices ranging from $957.00 to $957.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F10: Represents volume-weighted average price of sales of 244 shares of Company stock on November 17, 2026 at prices ranging from $958.12 to $958.44. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F11: Represents volume-weighted average price of sales of 506 shares of Company stock on November 17, 2026 at prices ranging from $959.03 to $959.86. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F12: Represents volume-weighted average price of sales of 257 shares of Company stock on November 17, 2026 at prices ranging from $960.10 to $960.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F13: Represents volume-weighted average price of sales of 584 shares of Company stock on November 17, 2026 at prices ranging from $961.07 to $961.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F14: Represents volume-weighted average price of sales of 295 shares of Company stock on November 17, 2026 at prices ranging from $962.17 to $962.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F15: Represents volume-weighted average price of sales of 255 shares of Company stock on November 17, 2026 at prices ranging from $963.28 to $963.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F16: Represents volume-weighted average price of sales of 340 shares of Company stock on November 17, 2026 at prices ranging from $964.03 to $964.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price. F17: The stock option award vested in four equal annual installments, commencing one year after the date of grant.